ImmunoGen Inc. of Cambridge, Mass., has named RobertConnaughton Jr. general counsel and John Knox director of humanresources. Connaughton had been president and chief operatingofficer of BancIreland/First Financial Inc. Knox came to ImmunoGenfrom Procept Inc., where he was also director of human resources.
Anthony Chan has been appointed chief financial officer at CygnusTherapeutic Systems Inc. He had been corporate controller of theRedwood City, Calif., company.
VitaMed Inc., a Seattle-based biotech subsidiary of the Canadiancompany VitaMed Biopharmaceuticals Ltd., has hired CliveWoodhouse as director of research and product development.Woodhouse had been the director of human monoclonal antibodydevelopment at GenPharm International.
Metasyn Inc. of Cambridge, Mass., has hired Richard Walovitch asvice president of preclinical and clinical research. Walovitch joinsMetasyn from DuPont Merck Pharmaceutical Co., where he was theglobal project clinician for the brain-imaging agent Neurolite.
Protein Design Labs Inc. of Mountain View, Calif., has electedpharmaceutical executive Max Link as a director. Link is also the newchief executive officer of Corange Ltd., a London-based privatehealth-care company. He resigned his post as chairman of SandozPharma Ltd., the pharmaceutical unit of Sandoz Ltd., effective theend of June.
Creative BioMolecules Inc. of Hopkinton, Mass., has elected MichaelRosenblatt to its board of directors. Rosenblatt is the Ebert professorof molecular medicine at Harvard Medical School, director of thedivision of bone and mineral metabolism at Beth Israel Hospital, anddirector of the Harvard-MIT division of health sciences andtechnology.
William Good has joined Salt Lake City-based TheraTech Inc. as vicepresident of development. Good had been the executive director incharge of Ciba-Geigy's worldwide development of transdermal drugdelivery systems.
(c) 1997 American Health Consultants. All rights reserved.